The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | How could immunotherapy alter the treatment landscape for Richter’s transformation?
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, comments on the potential of immunotherapy in Richter’s transformation (RT), highlighting a trial in which zanubrutinib and tislelizumab demonstrated promising and durable results in this difficult-to-treat patient population. Dr Eichhorst also mentions the potential of bispecific antibodies, such as epcoritamab. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We did a trial where we evaluated zanubrutinib with the checkpoint inhibitor tislelizumab. And actually the results with an overall response of 60% are really exciting in my opinion. So the median PFS is you could say 10 months only, but this is for Richter transformation, and already a very good result. And in particular we are excited that we do have now among those patients who respond a significant number of patients from these 46 patients included who are still on treatment...
We did a trial where we evaluated zanubrutinib with the checkpoint inhibitor tislelizumab. And actually the results with an overall response of 60% are really exciting in my opinion. So the median PFS is you could say 10 months only, but this is for Richter transformation, and already a very good result. And in particular we are excited that we do have now among those patients who respond a significant number of patients from these 46 patients included who are still on treatment. So in in some of the centers there are patients who are on the third year with Richter transformation on this immunotherapy and we think the reason why the immunotherapy may work here but in combination with the BTK inhibitor is a different genetic profile and therefore that the cells of the Richter transformation are more exposed to the immune system and therefore that these agents may work better. What other compounds as immunotherapies certainly of interest are the bispecific antibodies as epcoritamab, which are also discussed here on this meeting.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Miltenyi: Consultancy; MSD: Consultancy, Speakers Bureau; Hoffmann-La Roche: Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; Kite: Consultancy, Speakers Bureau; BeiGene: Consultancy, Research Funding, Speakers Bureau; Roche: Research Funding, Speakers Bureau; AbbVie: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Research Funding, Speakers Bureau; Lilly: Consultancy.
